Enhanced progenitor cell recruitment and endothelial repair after selective endothelial injury of the mouse kidney.
Primary and/or secondary injury of the renal microvascular endothelium is a common finding in various renal diseases. Besides well-known endothelial repair mechanisms, including endothelial cell (EC) proliferation and migration, homing of extrinsic cells such as endothelial progenitor cells (EPC) and hematopoietic stem cells (HSC) has been shown in various organs and may contribute to microvascular repair. However, these mechanisms have so far not been studied after selective microvascular injury in the kidney. The present study investigated the time course of EPC and HSC stimulation and homing following induction of selective EC injury in the mouse kidney along with various angiogenic factors potentially involved in EC repair and progenitor cell stimulation. Erythropoietin was used to stimulate progenitor cells in a therapeutic approach. We found that selective EC injury leads to a marked stimulation of EPCs, HSCs, and various angiogenic factors to orchestrate microvascular repair. Angiogenic factors started to increase as early as 30 min after disease induction. Progenitor cells could be first detected in the circulation and the spleen before they selectively homed to the diseased kidney. Injection of a high dose of erythropoietin 2 h after disease induction markedly attenuated vascular injury through nonhemodynamic mechanisms, possibly involving vascular endothelial growth factor release.
Hohenstein
Bernd
B
Division of Nephrology, Department of Internal Medicine III, University of Technology Dresden, Germany. bernd.hohenstein@uniklinikum-dresden.de
Kuo
Mei-Chuan
MC
Addabbo
Francesco
F
Yasuda
Kaoru
K
Ratliff
Brian
B
Schwarzenberger
Claudia
C
Eckardt
Kai-Uwe
KU
Hugo
Christian P M
CP
Goligorsky
Michael S
MS
D042501:Angiogenic Proteins / Q000378:metabolism; D000818:Animals; D002465:Cell Movement / Q000187:drug effects; D004195:Disease Models, Animal; D042783:Endothelial Cells / Q000187:drug effects / Q000378:metabolism / Q000473:pathology*; D004730:Endothelium, Vascular / Q000187:drug effects / Q000378:metabolism / Q000473:pathology* / Q000503:physiopathology; D004906:Erythrocyte Count; D004921:Erythropoietin / Q000008:administration & dosage; D049452:Green Fluorescent Proteins / Q000235:genetics / Q000378:metabolism; D006412:Hematopoietic Stem Cells / Q000187:drug effects / Q000378:metabolism / Q000473:pathology*; D007274:Injections, Intraperitoneal; D007668:Kidney / Q000098:blood supply*; D051379:Mice; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D008833:Microcirculation; D011401:Promoter Regions, Genetic; D042787:Receptor, TIE-2 / Q000235:genetics; D012079:Renal Circulation; D013154:Spleen / Q000378:metabolism / Q000473:pathology; D013234:Stem Cells / Q000187:drug effects / Q000378:metabolism / Q000473:pathology*; D057049:Thrombotic Microangiopathies / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology* / Q000503:physiopathology; D013997:Time Factors
D042501:Angiogenic Proteins; D004921:Erythropoietin; D049452:Green Fluorescent Proteins; D042787:Receptor, TIE-2